Treats Clostridioides difficile -associated diarrhea. ANDA 65478, held by Pai Holdings. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 65478 (Vancomycin Hydrochloride), held by Pai Holdings, was first approved by FDA on Apr 9, 2012, with 2 approved supplements and 0 published complete response letters.
Vancomycin hydrochloride capsule is indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin hydrochloride capsule is also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. Limitations of Use
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 9, 2012 | Original application | Approved |
| Vancomycin HydrochlorideEQ 125MG BASE · capsule;oral | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 250MG BASE · capsule;oral | Vancomycin Hydrochloride | Rx |
| Mar 15, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 15, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 9, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters